Reading, United Kingdom (02 March 2018) - Convatec Group Plc ("Convatec") a leading global medical products and technologies company focused on therapies for the management of chronic conditions, today announces the acquisition of J&R Medical LLC ("J&R Medical"), a Texas-based independent distributor of catheter-related supplies. Forthe year ended 31 December 2017 J&R Medical delivered revenues of approximately $9.0 million.
Paul Moraviec, CEO of Convatec, said: "The addition of J&R Medical to our Home Distribution Group will strengthen our presence in a substantial and important US market. The acquisition also reinforces Convatec's position as a leading distributor of urinary catheters in the US."
Concurrently with this strategic addition to the US Home Distribution Group, Convatec has divested its respiratory delivery business in Arizona and Utah. The net financial impact to Convatec of these transactions is positive in both revenue and EBITDA.
Bobby Leach, VP Group Corporate Affairs, Convatec +44 (0)7770 842 226
Alastair Elwen, Finsbury +44 (0)207 251 3801
Analysts and Investors
John Crosse, VP Investor Relations, Convatec +44 (0)7500 141 435
Kirsty Law, Director Investor Relations, Convatec +44 (0)7470 909 582
Convatec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion devices. Convatec's products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about Convatec, please visit www.convatecgroup.com where a copy of this announcement can also be found.
Download PRESS RELEASEPDF
Q1 Trading Update for the three months ended 31 March 2018Read more
Convatec announces changes within its U.S. Home Distribution GroupRead more
Convatec announces 2018 Interim ResultsRead more
03 July 2018 - Board ChangesRead more
Convatec Receives U.S. FDA 510(k) Clearance for Avelle™ Negative Pressure Wound Therapy SystemRead more
Trading update for the three months ended 30 September 2018 and change in FY 2018 guidanceRead more
Retirement of Chief Executive Officer and appointment of Rick Anderson as Chief Executive Officer (Interim)Read more
US FDA 510(k) clearance for AQUACEL™ Ag AdvantageRead more